|
May 12
|
US$3.50 - That's What Analysts Think Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Is Worth After These Results
|
|
May 12
|
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2024 Earnings Call Transcript
|
|
May 11
|
Sangamo Therapeutics First Quarter 2024 Earnings: US$0.27 loss per share (vs US$0.13 profit in 1Q 2023)
|
|
May 10
|
Sangamo Therapeutics Reports Q1 2024 Results: A Deep Dive into Financials and Strategic Highlights
|
|
May 9
|
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue Estimates
|
|
May 9
|
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
|
|
May 9
|
Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing
|
|
May 2
|
Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates
|
|
May 2
|
Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
|
|
Apr 22
|
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
|
|
Mar 25
|
What You Need To Know About The Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Analyst Downgrade Today
|
|
Mar 22
|
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
|
|
Mar 14
|
Sangamo Therapeutics Full Year 2023 Earnings: Misses Expectations
|
|
Mar 14
|
Q4 2023 Sangamo Therapeutics Inc Earnings Call
|
|
Mar 13
|
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
|
|
Mar 13
|
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
|
|
Mar 12
|
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
|
|
Oct 24
|
Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
|
|
Sep 4
|
Recent uptick might appease Sangamo Therapeutics, Inc. (NASDAQ:SGMO) institutional owners after losing 82% over the past year
|
|
Jul 20
|
Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing
|